These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29464017)

  • 1. Regulation of E-cadherin localization by microtubule targeting agents: rapid promotion of cortical E-cadherin through p130Cas/Src inhibition by eribulin.
    Dybdal-Hargreaves NF; Risinger AL; Mooberry SL
    Oncotarget; 2018 Jan; 9(5):5545-5561. PubMed ID: 29464017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction: Regulation of E-cadherin localization by microtubule targeting agents: rapid promotion of cortical E-cadherin through p130CAS/Src inhibition by eribulin.
    Dybdal-Hargreaves NF; Risinger AL; Mooberry SL
    Oncotarget; 2019 Jul; 10(45):4719-4720. PubMed ID: 31384398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eribulin and Paclitaxel Differentially Alter Extracellular Vesicles and Their Cargo from Triple-Negative Breast Cancer Cells.
    Pederson PJ; Liang H; Filonov D; Mooberry SL
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34205051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eribulin Activates the cGAS-STING Pathway via the Cytoplasmic Accumulation of Mitochondrial DNA.
    Fermaintt CS; Takahashi-Ruiz L; Liang H; Mooberry SL; Risinger AL
    Mol Pharmacol; 2021 Oct; 100(4):309-318. PubMed ID: 34312217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microtubule-Targeting Agents Eribulin and Paclitaxel Differentially Affect Neuronal Cell Bodies in Chemotherapy-Induced Peripheral Neuropathy.
    Benbow SJ; Wozniak KM; Kulesh B; Savage A; Slusher BS; Littlefield BA; Jordan MA; Wilson L; Feinstein SC
    Neurotox Res; 2017 Jul; 32(1):151-162. PubMed ID: 28391556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eribulin targets a ch-TOG-dependent directed migration of cancer cells.
    Chanez B; Gonçalves A; Badache A; Verdier-Pinard P
    Oncotarget; 2015 Dec; 6(39):41667-78. PubMed ID: 26497677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesenchymal-epithelial Transition and Tumor Vascular Remodeling in Eribulin Chemotherapy for Breast Cancer.
    Kashiwagi S; Asano Y; Goto W; Takada K; Takahashi K; Hatano T; Tanaka S; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Jan; 38(1):401-410. PubMed ID: 29277801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Src kinase inhibition restores E-cadherin expression in dasatinib-sensitive pancreatic cancer cells.
    Dosch AR; Dai X; Gaidarski Iii AA; Shi C; Castellanos JA; VanSaun MN; Merchant NB; Nagathihalli NS
    Oncotarget; 2019 Feb; 10(10):1056-1069. PubMed ID: 30800218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast Cancer Cell Lines Exhibit Differential Sensitivities to Microtubule-targeting Drugs Independent of Doubling Time.
    Risinger AL; Dybdal-Hargreaves NF; Mooberry SL
    Anticancer Res; 2015 Nov; 35(11):5845-50. PubMed ID: 26504006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple modes of action of eribulin mesylate: Emerging data and clinical implications.
    Cortes J; Schöffski P; Littlefield BA
    Cancer Treat Rev; 2018 Nov; 70():190-198. PubMed ID: 30243063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition.
    Oba T; Ito KI
    Oncotarget; 2018 May; 9(33):22986-23002. PubMed ID: 29796167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokeratin 18 is necessary for initiation of TGF-β1-induced epithelial-mesenchymal transition in breast epithelial cells.
    Jung H; Kim B; Moon BI; Oh ES
    Mol Cell Biochem; 2016 Dec; 423(1-2):21-28. PubMed ID: 27734227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Microtubule Destabilizer Eribulin Synergizes with STING Agonists to Promote Antitumor Efficacy in Triple-Negative Breast Cancer Models.
    Takahashi-Ruiz L; Fermaintt CS; Wilkinson NJ; Chan PYW; Mooberry SL; Risinger AL
    Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression.
    Ji Q; Liu X; Han Z; Zhou L; Sui H; Yan L; Jiang H; Ren J; Cai J; Li Q
    BMC Cancer; 2015 Mar; 15():97. PubMed ID: 25884904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Posttranslational modification of E-cadherin by core fucosylation regulates Src activation and induces epithelial-mesenchymal transition-like process in lung cancer cells.
    Shao K; Chen ZY; Gautam S; Deng NH; Zhou Y; Wu XZ
    Glycobiology; 2016 Feb; 26(2):142-54. PubMed ID: 26443198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eribulin Does Not Prevent Epithelial-to-Mesenchymal Transition in HT-29 Intestinal Epithelial Cells.
    Leutenegger M; Bruckner R; Spalinger MR; Lang S; Rogler G; Scharl M
    Inflamm Intest Dis; 2018 Jul; 2(4):211-218. PubMed ID: 30221148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TGFβ induces epithelial-mesenchymal transition of thyroid cancer cells by both the BRAF/MEK/ERK and Src/FAK pathways.
    Baquero P; Jiménez-Mora E; Santos A; Lasa M; Chiloeches A
    Mol Carcinog; 2016 Nov; 55(11):1639-1654. PubMed ID: 26392228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.
    Dybdal-Hargreaves NF; Risinger AL; Mooberry SL
    Clin Cancer Res; 2015 Jun; 21(11):2445-52. PubMed ID: 25838395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autophagy links β-catenin and Smad signaling to promote epithelial-mesenchymal transition via upregulation of integrin linked kinase.
    Pang M; Wang H; Rao P; Zhao Y; Xie J; Cao Q; Wang Y; Wang YM; Lee VW; Alexander SI; Harris DC; Zheng G
    Int J Biochem Cell Biol; 2016 Jul; 76():123-34. PubMed ID: 27177845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential Morphological and Biochemical Recovery from Chemotherapy-Induced Peripheral Neuropathy Following Paclitaxel, Ixabepilone, or Eribulin Treatment in Mouse Sciatic Nerves.
    Cook BM; Wozniak KM; Proctor DA; Bromberg RB; Wu Y; Slusher BS; Littlefield BA; Jordan MA; Wilson L; Feinstein SC
    Neurotox Res; 2018 Oct; 34(3):677-692. PubMed ID: 30051419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.